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The clinical management of adults with low-grade gliomas (LGGs) remains a challenge. There is no curative treatment, and
management of individual patients is a matter of deciding optimal timing as well as right treatment modality. In addition to
conventional imaging techniques, positron emission tomography (PET) with amino acid tracers can facilitate diagnostic and
therapeutic procedures. In this paper, the clinical applications of PET with amino acid tracers 11C-methyl-L-methionine (MET)
and 18F-ﬂuoro-ethyl-L-tyrosine (FET) for patients with LGG are summarized. We also discuss the value of PET for the long-term
followup of this patient group. Monitoring metabolic activity by PET in individual patients during course of disease will provide
insight in the biological behavior and evolution of these tumors. As such, spatial changes in tumor activity over time, including
shifts of hot-spot regions within the tumor, may reﬂect intratumoral heterogeneity and correlate to clinical parameters.
1. Low-GradeGliomas
1.1. Introduction. Low-grade gliomas (LGGs) in adults are
brain tumors aﬀecting otherwise healthy people with an
average age of around 40 years at the time of diagnosis.
The common histological types of LGGs are astrocytomas,
oligodendrogliomas, and oligoastrocytomas of malignancy
grade II according to the WHO classiﬁcation [1]. These
are poorly circumscribed diﬀusely inﬁltrative tumors with a
preferential localization in or close to eloquent areas [2].
The most frequent presenting symptoms are seizures.
Around 65–90% of all patients present with seizures, and
epilepsy may be the only symptom for months or years
in the initial phase of disease [3]. The median survival
of patients with LGGs is 5–10 years, but clinical outcome
varies considerably [4]. For some patients, the disease has an
indolentcourse,whereasothersexperiencerapidprogression
from disease presentation [5]. Patients with astrocytomas
carry the highest risk for malignant transformation, their
o v e r a l l5 - y e a rs u r v i v a lh a sb e e ne s t i m a t e da r o u n d5 0 %[ 6].
Patients with oligodendrogliomas have a more favorable
prognosis with a 5-year survival of 70–80% [4, 7]. It is
generally believed that in most patients, if not all, the tumor
will eventually transform into a malignant glioma with fatal
outcome.
1.2. Clinical Management. Treatment is unsatisfactory and
there are still controversies in the clinical management of
patients with LGGs [8]. No randomized studies are available
that have proven the role of surgery, but the consensus
today is that radical tumor resection is associated with a
favorable outcome [7, 9, 10]. Two large prospective trials on
radiotherapy in LGGs have failed to show a radiotherapeutic
doseresponse[11–13],withreducedqualityoflifeafterhigh-
dose radiotherapy compared to low dose [14]. A randomized
trial on the optimal timing of radiotherapy showed a longer
symptom-free survival by immediate postoperative radio-
therapy but no overall survival beneﬁt compared to radio-
therapyatthetimeofprogression[15].Chemotherapyasini-
tial treatment after surgery may be eﬀective and considered
for high-risk patients, including patients with large tumor
volumes and incomplete resections [16–19]. In general,2 International Journal of Molecular Imaging
the chemosensitivity of oligodendroglial tumors is higher
than of astrocytic tumors, being associated with the loss of
heterozygosity (LOH) on chromosome 1p and 19q [20].
1.3. Deﬁnition of the Clinical Problem. Favorable prognostic
factors identiﬁed from the randomized radiotherapy trials
in LGGs are young age (<40 year), histological subtype
of oligodendroglioma, good clinical status at disease onset,
seizures as only symptom, and relatively small tumor size
[21]. Thus, the total number of unfavorable factors at tumor
presentation can be determined and used as a prognostic
score for individual patients. Up to two factors identiﬁes
low-risk patients, whereas more than two identiﬁes high-risk
patients [21]. High-risk patients are identiﬁed for immediate
postoperative tumor treatment, while low-risk patients are
subsided to “watchful waiting”.
In spite of careful monitoring of symptoms and
radiological ﬁndings, the assessment of early tumor progres-
sion in individual patients may be diﬃcult. LGGs are gen-
erally nonenhancing tumors, and standard MRI protocols
enhancedwithgadoliniumshowlimitationsforevaluationof
LGGs [22, 23]. Another diﬃculty is the interpretation of sta-
ble disease. It has become clear that from a radiological point
of view, there is no such state as stable disease. Volumetric
studies by repeated MRI have demonstrated continuous
tumor growth during the clinically stable phase of disease
[24–26]. Thus, in addition to measuring volumetric tumor
growth by MRI, there is a need for imaging techniques that
reﬂect tumor activity.
Positron emission tomography (PET) can be used to
measure the metabolic activity of gliomas and has been
useful in various clinical situations. In this paper, the
current knowledge on the applications of PET for LGGs
is discussed, with focus on amino acid tracers, and rec-
ommendations are made for future studies. Literature ref-
erences were identiﬁed through searches of PubMed with
the search terms “low-grade glioma”, “PET”, “11C-methyl-
L-methionine (MET)”, “18F-ﬂuoro-ethyl-L-tyrosine (FET)”,
18F-ﬂuoro-L-dihydroxyphenylalanine (FDOPA), “radiother-
apy”, “chemotherapy”, “prognosis”, “survival”, and “progres-
sion” from 1990 until 2010. Articles were identiﬁed also
through searches of the authors’ own ﬁles including infor-
mation from international congress proceedings specialized
onclinicalneuro-oncology.OnlypaperspublishedinEnglish
were reviewed.
2. Positron Emission Tomography (PET)
Positron emission tomography (PET) has been used for over
two decades to image cancer metabolism. The most promi-
nent example is the use of 18F-ﬂuorodeoxyglucose (FDG),
a radiotracer derived from 2-deoxy-d-glucose, to study the
ﬁrst steps of glucose metabolism. FDG PET is used to stage
cancer and to diﬀerentiate between malignant and benign
lesions [27]. In neuro-oncology, the largest experience has
been acquired with FDG PET. Malignant brain tumors are
characterized by an increase in glucose consumption and
therelationshipbetweenhistologicalfeaturesandradiotracer
uptake is well established [28, 29]. As a consequence, FDG
PET is a valuable tool for guidance of stereotactic biopsies in
human gliomas [30].
The increased protein metabolism in cancer cells com-
pared to normal cells, assessed by radiolabeled amino acids,
are other targets for metabolic tumor imaging. 11C-methyl-
L-methionine (MET), the most frequently studied PET
tracer, has a half-life of 20 minutes and is regarded as
especially suitable for imaging of brain tumors [31]. The
uptake of MET is mainly determined by a speciﬁc carrier-
mediated mechanism and correlates with the proliferative
activity and microvessel density of the tumor cells [32–35].
The MET uptake in gliomas is inﬂuenced by its speciﬁc
activityinplasma,thetransferacrosstheblood-brainbarrier,
the intracellular metabolism, and the incorporation of MET
in proteins [36, 37]. Although disruption of the blood-
brain barrier is not a prerequisite for increased MET uptake,
a damaged blood-brain barrier may enhance leakage of
the tracer to the extracellular space and contribute to
the increased uptake in malignant gliomas [38]. MET is
considered the molecule of choice for gliomas, in spite of
its quantiﬁcation of incorporation which is more diﬃcult
compared to FDG [39, 40]. The superiority of MET PET
over FDG PET for evaluating glioma is based on the low
background uptake of MET in normal brain, providing good
contrast with tumor uptake. In accordance, MET is better
than FDG in delineating gliomas [40]. However, inter- and
intraindividual variations in MET uptake may occur, due to
methodological diﬀerences but also to competition for the
transporter protein by MET and other amino acids [41].
Fasting the patient before PET scan reduces the variability in
circulating amino acids, but local variations in MET uptake
may still occur, and careful standardization with precise
localization of reference regions is important especially for
tumors located at the border of gray and white matter [41].
The major drawback of MET is its short half-life of only
20 minutes, requiring an on-site cyclotron for production.
More recently, the tracer 18F-ﬂuoro-ethyl-L-tyrosine (FET)
has been established for biopsy guidance and treatment
planning of gliomas [42]. The advantage of FET is the longer
half-life of 109 minutes, enabling tracer production in a
central cyclotron and transport to other units. Although
the amino acid is not incorporated into proteins, the inﬂux
of FET is mediated by active transendothelial amino acid
transport [42]. FET PET measures the magnitude of amino
acid transport and its distribution in the tumor. Studies in
glioma have suggested similar results for FET PET and MET
PET [42–45]. The uptake of MET and FET occurs to a large
extentindependentlyofblood-brainbarrierdisturbance,and
shows a very similar uptake intensity and distribution in
brain tumors. The experience of FET PET in gliomas is still
somewhat limited compared to MET PET.
18F-ﬂuoro-L-dihydroxyphenylalanine (FDOPA) is an-
other 18F-labeled amino acid analog that has been used for
many years to visualize the integrity of the striatal dopamin-
ergic system in patients with movement disorders [46].
FDOPA is brought into tumor cells by amino acid trans-
portersandthetracercanbeusedalsotodetectbraintumors
[47]. FDOPA was found more accurate than FDG, as well as
the nucleoside 18F-ﬂuoro-thymidine (FLT) used as a markerInternational Journal of Molecular Imaging 3
(a) (b)
Figure 1: Transaxial postgadolinium T1-weighted MRI (a) and
fused MET PET-MRI (b) for spatial correlation of the MET uptake
in a glioma in the left frontotemporal region.
for cell proliferation, in detecting LGGs [48, 49]. A corre-
lation between FDOPA uptake and the malignancy grade
of newly diagnosed gliomas was recently demonstrated, and
futurestudiesmayestablisharoleforFDOPAasaprognostic
marker in gliomas [50].
3. Measurementof Biological Processes byPET
Initial PET studies in gliomas and other cancers were
performed as kinetic tracer studies, characterizing time-
activity curves of tracer uptake over the entire acquisition
period[51].Intheclinicalsetting,dynamicMETPETstudies
are not necessary and can be replaced by simpler protocols
calculating uptake ratios in the steady state phase of the
tracer. With the introduction of the tracer FET, dynamic
studies have again received attention, showing increased
diagnostic power and prediction of clinical outcome in
gliomas [52, 53].
Nowadays, PET images are integrated with CT or MR
images to map metabolic activity with anatomical regions
and structures in the brain (Figure 1). Quantiﬁcation of
tracer uptake by region of interest (ROI) analysis is per-
formed by using a threshold-based algorithm in this area for
the lesion itself and for normal brain areas, usually the cortex
of the healthyhemisphere or the cerebellum. Tumor volumes
are calculated and hot-spot ratios in the tumor, representing
areas with highest uptake, by comparing tumor-to-normal
brain ratios. In some studies, the parameter “activity tumor
volume” is used, deﬁned by calculating tumor volume
combined with mean tumor activity [54].
Tumor margins of LGGs are often wider estimated by
MET than assessed on T1-weighted contrast-enhanced MRI
[22, 23, 55]. A direct local comparison of signal changes
on presurgical MRI and MET with stereotactic biopsies
showed that MET detected solid tumor components as well
as inﬁltration areas with high sensitivity and speciﬁcity,
providing histological proof for the superior role of MET in
delineating tumor extent of gliomas [56]. Interestingly, the
inﬁltrativepartofLGGsincludedinthisstudyshowedhigher
MET uptake compared with the corresponding solid tumor
(a) (b)
Figure 2: MET PET of a patient with an oligodendroglioma in the
right parietal lobe before (a) and after (b) surgical resection and
adjuvant radiotherapy, showing no signs of residual tumor at 12
months posttherapy.
bulk, suggesting that areas of tumor invasion may have a
higher demand for amino acids such as methionine [56].
Perfusion studies, using dynamic susceptibility contrast
perfusion MRI, in combination with PET have established
a positive correlation between MET uptake and tumor
vascularity in gliomas [57, 58]. The regional cerebral blood
volume (rCBV) of the tumors correlated strongly with
MET uptake and was signiﬁcantly higher in high-grade
than in low-grade gliomas [57]. Stereotactic coregistration
of CBV and MET showed that both imaging parameters
wereassociatedwithhistopathologicalfeaturesofendothelial
proliferation and mitotic activity but not with necrosis [58].
Low-grade oligodendrogliomas show a generally higher
MET uptake than astrocytomas of similar malignancy grade
in spite of their more indolent clinical behavior. Higher MET
uptake in oligodendrogliomas is probably correlated to a
highercelldensityandlargercellturninoligodendrogliomas
comparedtoastrocytictumors[59].Oligodendrogliomasare
also known to have a higher microvessel density, consistent
with increased CBV values found in oligodendrogliomas
[57]. These data demonstrate that high microvessel density
in gliomas does not necessarily relate to endothelial cell
proliferation.
4. ClinicalApplications
In clinical daily practice, functional imaging techniques
are not always part of the primary diagnostic setup of
patients with suspected LGGs. Instead, they are used when
conventional diagnostics fail to give reliable information
or are considered too insensitive [51]( Figure 2). In such
situations, MET PET may change clinical decisions for
patients with brain tumor [68]. In addition to PET, advanced
MRI techniques may provide useful information during var-
ious stages of disease and improve outcomes for individual
patients. Although many of these advanced MR techniques
still need to be validated in clinical trials, they are likely to
ﬁnd a complementary role in the management of gliomas in
the near future [55].
4.1. Diﬀerentiating Tumor from Nontumor Lesions. MET
PET has been used for diﬀerential diagnosis of LGGs from
other nontumor lesions. Since MET uptake occurs mainly4 International Journal of Molecular Imaging
independently of blood-brain barrier disruption, LGGs are
generally visualized as hot areas irrespective of malignancy
grade. Acute inﬂammatory reactions in the brain, however,
may show increased MET uptake and lead to diﬀerential
diagnostic problems. The increased MET uptake in acute
inﬂammatory cells is caused by high metabolic rate of these
cells and high cell density but probably also by disruption of
the blood-brain barrier [69].
In spite of the widely accepted view that MET PET
can assist in diﬀerential diagnosis of tumor from nontumor
lesions, only few studies have provided evidence for this
clinical application of PET (Table 1). In a consecutive series
of 196 patients with suspected brain tumors, diﬀerentiation
between gliomas and nontumor lesions by MET PET was
correct in 79%, using a threshold of 1.47 for MET uptake
[60]. Diagnosis was veriﬁed by histological examination
in 170 patients or by clinical followup and additional
investigations (CSF examination or followup MRI) in the
remainder[60].Exclusionofhigh-gradegliomasreducedthe
sensitivity to67%, resultingin72%speciﬁcityfordiﬀerential
diagnosis of LGGs from nontumor lesions. Only 3 out of
31 astrocytomas grade II exhibited lower uptake values than
the normal contralateral cortex in this study [60]. In a
group of 39 children and young adults (2–21 years) with
suspected brain neoplasms, the diagnostic accuracy of MET
with regard to diﬀerentiating tumors from nontumor brain
lesions showed 83% sensitivity and 92% speciﬁcity [61].
In a recent study of 88 patients referred to a neurological
clinic because of brain lesions, FET PET was shown to
detect malignant gliomas with 93% sensitivity and low-
grade tumors with 68% sensitivity [62]. For 60 patients,
the diagnosis was conﬁrmed by histopathology within one
month following PET, for the remaining 28 patients by
clinical followup. Two false positive images were found of
a total of six postischemic lesions in this study, which was
thought related to the slow blood clearance of FET [62].
4.2. Guiding Stereotactic Procedures and Radiotherapy Plan-
ning. As mentioned, there is a correlation in gliomas
between MET uptake and tumor histology [51]. Conse-
quently, MET PET has been used for preoperative evaluation
of gliomas and, as a further development, for guidance of
stereotactic biopsies and radiosurgery [40]. The success rate
for PET-guided biopsies was found higher than with CT only
[64]. MET PET provided a more sensitive signal compared
to FDG PET [30]( Table 1). An increased uptake of both
tracers was found in histological samples with anaplasia,
but reduced uptake in necrotic areas was shown only by
MET [37, 70]( Table 1). Based on these results, MET PET is
considered as the molecule of choice for single-tracer PET-
guided biopsies in gliomas.
Since MET PET is a valuable instrument for measuring
tumor volume, the technique has been successfully used
for planning of target volume prior to radiotherapy. It is
of speciﬁc beneﬁt in LGGs that are ill deﬁned on MRI
[63]. This application has been conﬁrmed for FET PET in
patients with high-grade gliomas, but no data are available
yet for FET and LGGs. In a study of high-grade gliomas, a
high interrater agreement was found for biological tumor
volumes measured by FET PET-CT [71]. Less consistent
measures between observers were demonstrated when using
morphological tumor volumes on T1-weighted MRI [71].
It can be concluded that the available evidence supports
the role of MET and FET, above other PET tracers, as a
complement to volumetric MRI for radiotherapy treatment
planning.
4.3. Evaluation of Response to Radiotherapy. MET PET has
been evaluated in the followup after radiotherapy but mostly
by retrospective reviews including relatively few patients
(Table 1). In a postsurgical followup of 30 patients with
low-grade astrocytomas, no signiﬁcant diﬀerence in MET
a n dF D Gu p t a k ec o u l db ed e t e c t e db e t w e e nt u m o r sw i t h
or without adjuvant radiotherapy [65]. Other studies have
found a clear decline in mean MET uptake after radiother-
apy [66, 67]. These somewhat contradictory results may
be explained by diﬀerent observation times and diﬀerent
radiotherapy modalities used in the study protocols. MET
PET was found more suitable than FDG in monitoring
therapeutic eﬀects one year after interstitial brachytherapy
with 125I seeds [66, 67]. Interestingly, the largest decline in
MET uptake one year after 125I brachytherapy was shown in
tumors with high basal MET uptake, suggesting that MET
PET can be used as a marker for radiosensitivity in these
tumors [67].
4.4. Evaluation of Response to Chemotherapy. Several reports,
all based on limited numbers of patients, have shown
a decrease in MET uptake after chemotherapy in LGGs.
Reduced MET uptake in hot spots has consistently been
reported,butalso,reductionsoftumorvolumewereinduced
by chemotherapy (Table 2). Compared to MRI with ﬂuid-
attenuated inversion recovery (FLAIR) technique, MET
PET was found more sensitive for the assessment of PCV
responsiveness [54]. In a recent prospective study, FET PET
was used to evaluate the response to temozolomide in 11
patientswithprogressivenonenhancingLGGsandcompared
to MRI [72]. A reduction of FET uptake as early as one
month after initiated treatment, preceding MRI volume
reductions by several months, was found in some tumors,
underscoring the sensitivity of PET with amino acid tracers
for detecting early treatment response [72]( Table 2).
4.5. Diﬀerentiating Recurrent Tumor from Radionecrosis. Tis-
sue necrosis induced by radiotherapy may cause diﬀerential
diagnostic problems between treatment eﬀects and recurrent
or progressive tumor disease for conventional MRI [55].
Traditionally, FDG PET has been used for this speciﬁc
application although the low sensitivity of the method has
limited its use [80–82]. Chao and coworkers demonstrated
that coregistration of FDG PET with MRI increased the
sensitivity from 65% to 86% in metastatic brain tumors
[83]. More recently, MET PET was shown more successful
than FDG PET in diﬀerentiating contrast-enhancing areas
on MRI induced by radiotherapy from recurrent tumor
growth [73, 74]( Table 2). Eﬀective radiation resulted in
decreased MET uptake in the tumor, whereas increased MET
uptake was an indicator of progressive disease. There was noInternational Journal of Molecular Imaging 5
Table 1: Clinical applications of PET with amino acid tracers in adult low-grade gliomas (LGGs).
Study Study design Tumor subtype1
no. of patients Results and/or conclusion
Diﬀerential diagnosis tumor versus nontumor lesions
Herholz et al. [60]
Retrospective review
Consecutive suspected tumors
Measures: MET ratio, histology
196 patients (99 gliomas
grade II)
MET ratio 67% sensitivity and 72%
speciﬁcity for diﬀerential diagnosis
grade II gliomas versus nontumor
lesions
Galldiks et al. [61]
Consecutive series of children
and young adults (2–21 year)
with suspected tumors
Measures: MET ratio, histology
39 patients (6 AI, 6 AII,
4 AIII, 2 OAIII)
MET ratio 83% sensitivity & 92%
speciﬁcity for diﬀerential diagnosis
tumor versus nontumor lesions
Pichler et al. [62]
Retrospective review
Consecutive tumors or other
intracerebral lesions
Measures: FET ratio, MRI, histology
88 patients (19 gliomas
grade I and grade II)
FET ratio 94% sensitivity in HGG;
68% sensitivity in LGGs; 2 false
positive cases (postischemic lesions)
o u to f1 0n o n b i o p s yv e r i ﬁ e d
inﬂammatory lesions
Guiding stereotactic procedures and radiotherapy planning
Goldman et al. [37]
Retrospective review
Measures: MET ratio, FDG ratio,
stereotactic guided histology
14 gliomas (93 biopsies)
MET ratio correlates with anaplasia;
FDG ratio correlates with anaplasia;
inverse correlation MET ratio and
necrosis; no correlation FDG ratio and
necrosis
Levivier et al. [30]
Retrospective review
PET-guided radiosurgery
Measures: MET volume, MRI
5 LGGs
Spatial accuracy increased by MET
volume, especially in ill-deﬁned
lesions on MRI
Nuutinen et al. [63]
Prospective long-term followup
Measures: MET ratio, MET volume,
MRI, survival
14 gliomas (13 AII and
1AIII)
MET ratio and volume: 80%
sensitivity in detecting postoperative
residual tumor; beneﬁt for
radiotherapy planning in 3/14 patients
with inconclusive MRI
Pirotte et al. [64]
Retrospective review PET-guided
stereotactic biopsy
Measures: MET ratio, MET volume,
FDG ratio, FDG volume, histology
10 LGGs (6 AII, 2 OII, 1
g i a n tc e l la s t r o c y t o m a ,1
ganglioglioma)
MET ratio corresponded to histology
in 9 LGGs; FDG ratio corresponded to
histology in 1 LGGs; MET volume
superior to FDG volume, especially for
cortical tumors
Evaluation of response to radiotherapy
Roelcke et al. [65]
Postoperative followup of irradiated (n
= 13) and nonirradiated (n = 17)
patients
Measures: MET ratio, FDG ratio
30 AII
No diﬀerences in changes of MET and
FDG ratio over time between two
groups
Voges et al. [66]
Followup of 125I brachytherapy
Measures: FDG ratio and volume,
MET ratio, and volume
39 gliomas (17 AII, 2
OII, 5 OAII, 1 AI, 2
unspeciﬁed, 3 grade III,
8GB)
Minimal eﬀect of brachytherapy on
FGD ratio1 year after seed
implantation, but decline of MET ratio
W¨ urker et al. [67] Follow up of 125I brachytherapy
Measures: FDG ratio, MET ratio
10 LGGs (2 AI, 5 AII,
2 OAII, 1 OII)
Signiﬁcant decline in mean MET ratio
before and 1 year after brachytherapy;
no changes in mean FDG ratio;
highest decline rates in tumors with
high basal MET ratio
1Abbreviations: LGGs: low-grade gliomas; AI: pilocytic astrocytoma; AII: astrocytoma grade II; OII: oligodendroglioma grade II; OAII: oligoastrocytoma
grade II; AIII: astrocytoma grade III; OAIII: oligoastrocytoma grade III; GB: glioblastoma.
direct relationship between FDG and MET uptake ratios in
histological areas with necrosis, whereas areas with anaplasia
showed an increase uptake of both MET and FDG [73]. The
generally higher baseline MET uptake in oligodendroglial
tumors explained why MET PET provided better diagnostic
information with higher sensitivity in astrocytic tumors in
this study [73].
4.6. Long-Term Followup and Prognosis. Volumetric MRI
studies have shown continuous growth in LGGs before6 International Journal of Molecular Imaging
Table 2: Clinical applications of 11C-methionine uptake measured by PET in adult low-grade gliomas (LGGs).
Study Study design Tumor subtype1
no. of patients Results and/or conclusion
Evaluation of response to chemotherapy
Tang et al. [54]
Retrospective review Chemosensitivity
to PCV Measures: activity volume
index (AVI), FLAIR-MRI
7O I I
PCV associated with drastic
decrease in AVI; less pronounced
decrease in tumor volume on
FLAIR-MRI
Wyss et al. [72]
Prospective study TMZ in progressive
nonenhancing tumors Measures: FET
ratio, FET volume, and MRI
11 LGGs (3 OII,
4 AII, 4 AOII)
Changes in FET preceded and more
pronounced than MRI changes;
decrease FET ratio < FET volume in
responders
Diﬀerentiating recurrent tumor from changes induced by radiotherapy
Van Laere et al. [73]
R e t r o s p e c t i v er e v i e wD i ﬀerential
diagnosis radionecrosis-recurrence
Measures: MET ratio, FDG ratio,
histology, and survival
30 gliomas (15 LGGs:
8 AAII, 3 OAII, 4 OII)
FDG and MET ratio signiﬁcant
parameters for survival; FDG and
MET strongest prognostic accuracy;
MET alone strongest prognostic
factor for astrocytomas
Terakawa et al. [74]
R e t r o s p e c t i v er e v i e wD i ﬀerential
diagnosis radionecrosis-recurrence
Measures: MET ratio (L/Nmean,
L/Nmax, lesion/normal frontal cortex),
histology
77 patients (26 gliomas:
6 grade II, 6 grade III
and 14 GB; 51
metastases)
L/Nmean with cutoﬀ 1.58 most
informative for glioma (75%
sensitivity, 75% speciﬁcity); L/Nmax
not informative for glioma
Long-term followup and prognosis
Nuutinen et al. [63]
Prospective long-term followup
Measures: MET ratio, MET volume,
histology, and survival
14 gliomas (13 AII and
1 AIII)
Met ratio and volume: 80%
sensitivity in detecting residual
postoperative tumor; baseline MET
ratio of prognostic value
Ribom et al. [75]
R e t r o s p e c t i v er e v i e wP r e t r e a t m e n t
MET Measures: MET ratio, MET
volume (untreated versus after
surgery/radio- and/or chemotherapy),
time-to-progression (TPP)
32 LGGs (11 AII, 6 OAII,
15 OII)
Untreated patients: longest TTP
when stable MET ratio and small
volume increase; treated patients:
initial treatment eﬀects (reduction
MET ratio, volume or in both) but
no prognostic value
Ullrich et al. [76]
Prospective long-term followup
Measures: MET ratio, histology, and
molecular tumor proﬁle
24 gliomas (10 AII, 7
OAII, 1 OII,
3 AIII, 3 OAIII)
Mean increase of MET in patients
with progression 54.4% versus 3.9%
in patients with stable disease;
correlation increased MET and
VEGF expression
Ribom et al. [77]
R e t r o s p e c t i v er e v i e wP r e o p e r a t i v e
MET Measures: MET ratio, and
survival
89 LGGs (33 AII, 17
OAII, 39 OII)
Preoperative MET ratio prognostic
f a c t o rf o rs u r v i v a li nA I Ia n dO I I
De Witte et al. [78]
R e t r o s p e c t i v er e v i e wP r e o p e r a t i v e( n =
74) and postoperative (n = 11) MET
Measures: MET ratio, survival
85 gliomas (28 LGGs:
12 AII, 4 OAII, 12 OII)
MET ratio prognostic factor for
survival in grade II and grade III
gliomas
Floeth et al. [79]
Prospective followup Histologically
veriﬁed LGGs Measures: FET ratio,
growth pattern on MRI (diﬀuse versus
circumscribed), survival
33 LGGs (27 AII, 2 OAII,
4 OII)
3 major subtypes:
(1) low FET ratio and
circumscribed on MRI most
favorable outcome,
(2) positive FET ratio and
circumscribed on MRI intermediate
outcome,
(3) positive FET ratio and diﬀuse
on MRI unfavorable outcome
1Abbreviations: LGGs: low-grade gliomas; AI: pilocytic astrocytoma; AII: astrocytoma grade II; OII: oligodendroglioma grade II; OAII: oligoastrocytoma
grade II; AIII: astrocytoma grade III; OAIII: oligoastrocytoma grade III; GB: glioblastoma.International Journal of Molecular Imaging 7
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a
(c) (d) (e)
Figure3:METPETfromdiseaseonset(a)todiseaseprogression(e)ofapatientwithLGGsinthelefthemisphere,showingagradualincrease
in hot-spot activity during progressive disease. This patient received radiotherapy between the ﬁrst (a) and second PET investigation (b),
and chemotherapy between the second (b) and third (c) PET investigation. MET PET was performed at approximately 6 months intervals
from the time point of disease onset.
anaplastic transformation occurs, with predictable growth
rate within a relatively narrow range [24–26]. Ideally, PET
could be used to measure other parameters in addition to
tumor volume that reﬂect early tumor progression during
the time interval prior to accelerated growth on MRI or
clinical deterioration [84]. There is indirect support for such
a role of MET PET in LGGs, but more robust data are still
lacking. One long-term followup study has demonstrated
the role of PET in the assessment of time to progression
and treatment planning of individual patients [63]. Patients
with tumors that showed stable of reduced MET uptake
after radiotherapy lived longer in this series [63]. MET PET
was shown sensitive in detecting changes in tumor volume
over time in LGGs [75]. Combined information on changes
in tumor volume measured by MET PET and changes in
hot-spot activity over time improved the prediction of
time to progression in this retrospective case review [75].
Consistent ﬁndings of MET being a sensitive indicator for
malignant progression have been reported by Ullrich and
coworkers [76]. A signiﬁcant correlation between changes in
MET uptake during tumor progression and the expression of
vascular endothelial cells growth factor (VEGF) was found
in this study, suggesting that MET uptake may be a surrogate
marker for activated VEGF receptor signaling [76]. Baseline
uptake of MET at disease onset before treatment has been
identiﬁed as a prognostic factor for survival in patients with
LGGs [77, 78].
In a prospective study of LGGs, FET uptake together
with tumor growth pattern on MRI was shown to be a
strong prognostic factor [79]. Patients with diﬀusely
growing tumors and higher FET uptake ratios had the most
unfavorable outcome [79]. A threshold value for FET uptake
of 1.1 provided highest prognostic signiﬁcance, suggesting
thatthequalitativefeatureofincreaseduptakeitselfisamore
important factor for outcome than the absolute value of the
uptake ratio [79]. The observation that the tumor growth
pattern on MRI, in combination with the FET ratio, has a
prognostic impact is an interesting ﬁnding and illustrates the
importance of imaging tumor behavior in relation to clinical
outcome [85].
5. The NaturalHistoryof LGGs
Most PET studies on glioma have focused on measuring
MET in tumor areas with highest uptake in relation to
clinical parameters, such as tumor histology, response to
therapy and patient outcome. Less is known on the spatial
changes of MET and FET uptake taking place over time dur-
ing the natural course of this disease. Monitoring metabolic
tumor activity during the evolution of disease, including the
number and speciﬁc locations of hot spots, is probably a
valuable way to study biological tumor behavior.
From our own clinical experience of MET PET in
patients with LGGs, we have noticed that tumors may show
diﬀerent patterns of progression [75, 86]. In most patients,
progressive disease is accompanied by a gradual increase of
MET uptake in a preexisting hot-spot, suggesting malignant
transformation of this particular tumor area (Figure 3). In
other patients, new hot spots arise that may occur prior
to clinical and radiological progression and irrespective of
tumor treatment. Also, a shift in hot spot from one region to
another may be visible during course of disease, suggesting
the existence of multiple active metabolic sites within the
same tumor (Figure 4).
One could speculate that tumors comprising several
hot spots are biologically more heterogeneous and harbor
subclonesoftumorcellswithdiﬀerenttumorbehavior.Since
regional molecular heterogeneity is known to be present also
in histologically homogeneous glioma types such as LGGs, it
is possible that diﬀerent hot spot regions within one tumor
represent diﬀerent molecular subclones of tumor cells [87].
As a consequence, diﬀerent tumor areas can show diﬀerent
chemo- and radiosensitivity and MET PET is likely to be a
valuable tool to monitor such heterogeneity in response to
treatment [88].
Support for the existence of spatial heterogeneity in
LGGs has come from a PET study, correlating blood ﬂow
and FET uptake in a series of LGGs [89]. The majority
of tumors included in this study showed an increase of
global blood ﬂow in the tumor, measured by 15O-H2O,
together with an increase of FET. Increased blood ﬂow8 International Journal of Molecular Imaging
(a) (b) (c) (d)
Figure 4: MET PET from disease onset (a) to disease progression (d) of a patient with LGGs in the left hemisphere, showing a shift of
weak hot-spot activity located in the left frontotemporal region (a, b), towards a stronger and more centrally located hot spot (c, d) during
progressive disease. This patient received radiotherapy between the second (b) and third (c) PET investigation. MET PET was performed at
approximately 12 months intervals from the time point of disease onset.
correlated to increased FET uptake and was spatially coupled
to the center of the tumor [89]. In individual tumors,
however, a spatial heterogeneity was present with regard
to the distribution of amino acid uptake and blood ﬂow.
Thus, blood ﬂow could be low in spite of high amino
acid uptake at the tumor periphery, where inﬁltration of
tumor cells into the peritumoral brain occurs. Low blood
ﬂow together with high FET uptake was seen in tumors
inﬁltrating the corpus callosumand could reﬂecta mismatch
between metabolic demands and energy supply, promoting
hypoxia [89]. Interestingly, all tumors included in this study
appearedashomogeneousnongadoliniumenhancinglesions
on MRI.
6. Conclusions
LGGs are slowly growing tumors characterized by homo-
geneous histopathological features but with a large clinical
variability in response to treatment and clinical outcome.
The management of this patient group requires individual
treatment decisions and careful followup of individual
patients during the entire course of disease. PET with amino
acid tracers, integrated with MRI, is recommended for all
patients presenting with a presumed LGGs in clinical centers
that have access to PET. This PET examination at the
time point of disease presentation is of value for diﬀeren-
tial diagnosis, to guide stereotactic biopsy, for prognostic
assessment, and as a baseline study prior to postoperative
therapy. PET may also be used successfully at later clinical
time points, when planning for radiotherapy or evaluating
responsetotreatment.Theevidenceformostoftheseclinical
applications, however, is not strong and mainly based on
small retrospective studies. Further developments in this
ﬁeld will largely beneﬁt from larger clinical trials with
prospective study designs. In addition, long-term followup
of individual patients by PET will provide new insights into
tumor behavior in relation to clinical parameters for patients
with LGGs.
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